Pelvic exenteration for recurrent or persistent cervical cancer: Experience of five years at the National Cancer Institute in Mexico

Medical Oncology

Volumn 23, Issue 2, 2006, Pages 219-223

  Teran Porcayo M A ^a   Zeichner Gancz, I ^b   Gomez Del Castillo, R A C ^a   Beltran Ortega A ^b   Solorza Luna, G ^b  

^a Instituto Estatal de Cancerologia Dr Arturo Beltran Ortega   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Cervical cancer; Pelvic exenteration; Recurrence

Indexed keywords

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDICAL RECORD; OVERALL SURVIVAL; PELVIS EXENTERATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURGICAL TECHNIQUE; TIME SERIES ANALYSIS; UTERINE CERVIX CANCER;

EID: 33646881292     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:2:219     Document Type: Article

References (30)

1. Dirección General de Epidemiología. Registro histopatológico de neoplasias en México. Morbilidad y mortalidad 2001. México: SSA, 2004.
2. Waggoner SE. Cervical cancer. Lancet 2003;361:2217-2225.
3. DiSaia PJ, Creasman WT. Clinical Gynecology Oncology, fifth Edition; 1997:51-106.
4. Kuzuya K. Chemoradiotherapy for uterine cancer: current status and perspectives. Int J Clin Oncol 2004;9:458-470.
5. Long HJ, 3rd. Current research directions for locally advanced cervix cancer. Curr Oncol Rep 2003;5:468-472.
6. Shibata K, et al. Usefulness of preoperative chemoradiation in locally advanced cervical carcinoma. Gynecol Obstet Invest 2004;57:93-99.
7. Vrdoljak E, Hamm W. Current state-of-the-art of concomitant chemoradiation in cervical carcinomas. Eur J Gynaecol Oncol 2003;24:475-479.
8. Hockel M. Surgical treatment of locally advanced and recurrent cervical carcinoma: overview on current standard and new developments. Onkologie 2003;26:452-455.
9. Shingleton HM, Soong SJ, Gelder MS, Hatch KD, Baker VV, Austin JM, Jr. Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol 1989;73:1027-1034.
10. Brunschwig A, Pierce VK. Partial and complete pelvic exenteration; a progress report based upon the first 100 operations. Cancer 1950;3:972-974.
11. Graham JC, Pérez FJI. Evisceración pélvica por cáncer Avanzado. Rev Inst Nal Canc 1965;3:125-129.
12. Lopez MJ, Spratt JS Exenterative pelvic surgery. J Surg Oncol 1999;72:102-114.
13. Magrina JF, Stanhope CR, Weaver AL. Pelvic exenterations: supralevator, infralevator, and with vulvectomy. Gynecol Oncol 1997;64:130-135.
14. Rutledge FN, Smith JP, Wharton JT, O'Quinn AG. Pelvic exenteration: analysis of 296 patients. Am J Obstet Gynecol 1977;129:881-892.
15. Lawhead RA, Jr., Clark DG, Smith DH, Pierce VK, Lewis JL, Jr. Pelvic exenteration for recurrent or persistent gynecologic malignancies: a 10-year review of the Memorial Sloan-Kettering Cancer Center experience (1972-1981). Gynecol Oncol 1989;33:279-282.
16. Averette HE, Lichtinger M, Sevin BU, Girtanner RE. Pelvic exenteration: a 15-year experience in a general metropolitan hospital. Am J Obstet Gynecol 1984;150:179-184.
17. Anthopoulos AP, Manetta A, Larson JE, Podczaski ES, Bartholomew MJ, Mortel R. Pelvic exenteration: a morbidity and mortality analysis of a seven-year experience. Gynecol Oncol 1989;35:219-223.
18. Soper JT, et al. pelvic exenteration: factors associated with major surgical morbidity. Gynecol Oncol 1989;35:93-98.
19. Selman AE, Copeland LJ. Surgical management of recurrent cervical cancer. Yonsei Med J 2002;43(6):754-762.
20. Kecmanovic DM, et al. Management of advanced pelvic cancer by exenteration. Eur J Surg Oncol 2003;29:743-746.
21. Hatch KD, Shingleton HM, Soong SJ, Baker VV, Gelder MS. Anterior pelvic exenteration. Gynecol Oncol 1988;31:205-216.
22. Hockel M, Baussmann E, Mitze M, Knapstein PG. Are pelvic side-wall recurrences of cervical cancer biologically different from central relapses? Cancer 1994 15;74:648-655.
23. Goldberg JM, Piver MS, Hempling RE, Aiduk C, Blumenson L, Recio FO. Improvements in pelvic exenteration: factors responsible for reducing morbidity and mortality. Ann Surg Oncol 1998;5:399-406.
24. Rutledge S, Carey MS, Prichard H, Allen HH, Kocha W, Kirk ME. Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation: is exenteration always necessary? Gynecol Oncol 1994;52:353-359.
25. Tarraza HM, Ellerkmann RM. Pelvic radical surgery. Surg Oncol Clin N Am 1998;7(2):399-416.
26. Leitao MM, Jr, Chi DS. Recurrent cervical cancer. Curr Treat Options Oncol 2002;3:105-111.
27. Pandey D, Zaidi S, Mahajan V, Kannan R. Pelvic exenteration: A perspective from a regional cancer center in India. Indian J Cancer 2004;41:109-114.
28. Leitao MM, Jr, Chi DS. Recurrent cervical cancer. Curr Treat Options Oncol 2002;3:105-111.
29. Lambrou NC, Pearson JM, Averette HE. Pelvic exenteration of gynecologic malignancy: indications, and technical and reconstructive considerations. Surg Oncol Clin N Am 2005;14:289-300.
30. Salom EM, Penalver MA. Pelvic exenteration and reconstruction. Cancer J 2003;9:415-424.